文献速递认知障碍与痴呆

反义寡核苷酸降低ApoE4可减轻tau蛋白病模型中的神经退行性变

Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model.
PubMed 文献 · Ann Neurol · 2021-02-24

本研究在P301S/ApoE4 tau蛋白病小鼠模型中,于6和7.5月龄经脑室内注射靶向人APOE的反义寡核苷酸(ASO),9月龄时评估脑病理。结果显示ApoE ASO使ApoE4蛋白水平降低约50%,显著减轻tau病理及相关神经退行性变、减少神经炎症并保留突触密度,血浆NfL水平也显著下降。结论提示降低ApoE4水平值得作为APOE4携带者tau蛋白病(包括阿尔茨海默病)的潜在治疗策略进一步探索。

要点

  • 在P301S/ApoE4小鼠中,ApoE ASO使ApoE4蛋白降低约50%。
  • ApoE ASO显著减轻tau病理、神经退行性变和神经炎症,保留突触密度。
  • ASO治疗小鼠血浆NfL水平显著降低,支持降低ApoE4的治疗潜力。

核心结论

  • 降低ApoE4水平应作为APOE4携带者tau蛋白病(包括阿尔茨海默病)的治疗策略进一步探索。

研究设计与样本

  • 在P301S/ApoE4 tau蛋白病小鼠模型中,于6和7.5月龄经脑室内注射靶向人APOE的ASO或对照ASO,9月龄时进行脑病理评估。

主要发现

  • ApoE ASO治疗使ApoE4蛋白水平降低约50%。
  • ApoE ASO显著减轻tau病理及相关神经退行性变,减少神经炎症,并保留突触密度。
  • ASO治疗小鼠血浆神经丝轻链(NfL)蛋白水平显著降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Apolipoprotein E (ApoE) genotype is the strongest genetic risk factor for late-onset Alzheimer's disease, with the ε4 allele increasing risk in a dose-dependent fashion. In addition to ApoE4 playing a crucial role in amyloid-β deposition, recent evidence suggests that it also plays an important role in tau pathology and tau-mediated neurodegeneration. It is not known, however, whether therapeutic reduction of ApoE4 would exert protective effects on tau-mediated neurodegeneration. METHODS: Herein, we used antisense oligonucleotides (ASOs) against human APOE to reduce ApoE4 levels in the P301S/ApoE4 mouse model of tauopathy. We treated P301S/ApoE4 mice with ApoE or control ASOs via intracerebroventricular injection at 6 and 7.5 months of age and performed brain pathological assessments at 9 months of age. RESULTS: Our results indicate that treatment with ApoE ASOs reduced ApoE4 protein levels by ~50%, significantly protected against tau pathology and associated neurodegeneration, decreased neuroinflammation, and preserved synaptic density. These data were also corroborated by a significant reduction in levels of neurofilament light chain (NfL) protein in plasma of ASO-treated mice. INTERPRETATION: We conclude that reducing ApoE4 levels should be explored further as a therapeutic approach for APOE4 carriers with tauopathy including Alzheimer's disease. ANN NEUROL 2021;89:952-966.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Litvinchuk A, Huynh TV, Shi Y, et al. Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model. Ann Neurol. 2021. PMID: 33550655. doi:10.1002/ana.26043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。